EODData

MEMBERSHIP REGISTER LOG IN

FRA, 30S: SANIONA AB (PUBL)

20 Nov 2025
LAST:

1.530

CHANGE:
 0.08		OPEN:
1.530		HIGH:
1.530		ASK:
0.000		VOLUME:
110
CHG(%):
5.37		PREV:
1.452		LOW:
1.530		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
20 Nov 251.5301.5301.5301.530110
19 Nov 251.4521.4521.4521.452110
18 Nov 251.4441.4441.4441.444110
17 Nov 251.3741.3741.3741.374110
13 Nov 251.4521.4521.4521.452110
12 Nov 251.4481.4481.4481.448110
11 Nov 251.3961.3961.3961.396110
07 Nov 251.3921.3921.3921.392110
06 Nov 251.4781.4781.4781.4780
05 Nov 251.4501.4501.4501.450110

PROFILE

Name:SANIONA AB (PUBL)
About:Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; and ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor, a neurological disorder. It also develops SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures; SAN2355 to treat resistant focal onset seizures; and SAN2465, a negative allosteric modulator to treat major depressive disorder. In addition, the company's other programs to treat epilepsy, Alzheimer's, schizophrenia, and migraine. It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identify and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer's disease. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Sector:Healthcare
Industry:Biotechnology
Address:Murervangen 42, Glostrup, Denmark, 2600
Website:https://www.saniona.com
ISIN:SE0005794617
LEI:549300XO4L9XNOCFCZ84

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:7.84 
PEG Ratio:-1.41 
Price to Sales:0.63 
Price to Book:0.54 
Profit Margin:0.63 
Operating Margin:-2.64 
Return on Assets:0.56 
Return on Equity:1.18 
Revenue:30.86M 
EBITDA:20.16M 
Shares:138.03M 
Market Cap:211.19M 

TECHNICAL INDICATORS

MA5:1.455.5%
MA10:1.446.1%
MA20:1.3910.0%
MA50:1.2126.3%
MA100:1.0348.3%
MA200:0.8579.1%
STO9:100.00 
STO14:100.00 
RSI14:68.10 
MTM14:0.21
ROC14:0.16 
ATR:0.04 
Week High:1.530.0%
Week Low:1.3711.4%
Month High:1.530.0%
Month Low:1.2979.1%
Year High:1.530.0%
Year Low:0.21618.3%
Volatility:24.41